Last reviewed · How we verify
Continuation of own regimen — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Continuation of own regimen (Continuation of own regimen) — Radboud University Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Continuation of own regimen TARGET | Continuation of own regimen | Radboud University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Continuation of own regimen CI watch — RSS
- Continuation of own regimen CI watch — Atom
- Continuation of own regimen CI watch — JSON
- Continuation of own regimen alone — RSS
Cite this brief
Drug Landscape (2026). Continuation of own regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/continuation-of-own-regimen. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab